Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Introduction to HIV-1 and AIDS
- Understanding HIV-1 immunology
- The natural history of HIV-1 infection
- The virus particle
- Viral replication
- Cell-free vs. cell-cell HIV-1 spread
- Viral receptors and entry
- Virus cellular tropism
- Progression to AIDS and the immune response
- Non-specific generalised immune activation
- The vicious cycle of immune activation
- So, what causes AIDS?
- Innate immunity to HIV-1
- Restriction factors and viral antagonists
- Adaptative immunity to HIV-1
- Antibody responses to HIV-1
- HIV-1 vaccine approaches
- CTL-based vaccine approaches
- CTL-based vaccine approaches are challenging
- Neutralizing antibody vaccines are also challenging
- Broadly neutralizing antibodies (1)
- Broadly neutralizing antibodies (2)
- Viral reservoirs and latency
- Current approaches to an HIV-1 cure
- Summary and conclusions
- Some further reading
- Thank you for listening!
Topics Covered
- Replication and spread of HIV-1
- Viral immunopathology: AIDS
- Innate and adaptive immune responses to HIV-1
- HIV-1 vaccine design
- Viral reservoirs and potential cure
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Sattentau, Q. (2020, September 30). HIV and the immune system [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/ACCL9313.Export Citation (RIS)
Publication History
Financial Disclosures
- Quentin Sattentau has no commercial/financial relationships to disclose.
Other Talks in the Series: The Immune System - Key Concepts and Questions
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Quentin Sattentau,
I'm Professor of Immunology at the Sir William Dunn School of Pathology,
at the University of Oxford, UK.
The title of my lecture is HIV and the Immune System.
0:16
Again, to start with a brief introduction to HIV-1 and AIDS,
there are two types of human immunodeficiency virus or HIV for short, HIV-1 and HIV-2.
Today, we're going to focus on HIV-1.
HIV-1 is responsible for the global pandemic of about 37 million infected people.
HIV-1 infects cells of the immune system,
primarily CD4 T lymphocytes,
also known as CD4+ T cells.
The death of CD4+ T cells causes acquired immune deficiency syndrome or AIDS.
AIDS is the loss of immune competence to fight opportunistic infections and some cancers.
HIV-1 elicits innate and adaptive immune responses,
but evades these responses.
HIV-1 also forms long-lived latent reservoirs preventing viral eradication.
1:15
In order to understand HIV immunology,
we need to address the following questions.
How does HIV-1 infect and replicate in CD4 T cells and other relevant immune cells?
How does the virus cause immune pathology driving AIDS?
What is the immune response to HIV-1,
and how is this evaded by the virus?
What are we doing to develop a vaccine?
Can we eliminate HIV-1 from the infected host?